Prophylactic and therapeutic ruxolitinib use alleviates acute colitis in murine model. A, Schematic showing dextran sulfate sodium (DSS) treatment and ruxolitinib treatment (n = 8-10 per group). B, Percentage weight change from baseline in the groups. C, Gross morphology of colon tissue. D, Colon length in the 4 groups. E, Hematoxylin and eosin staining of colon tissue in the 4 groups. F, Histological grading of mice in each group. G, Survival in each group. H, Comparison of disease activity index (DAI) scores among the groups. I, Schematic showing TNBS treatment and ruxolitinib treatment (n = 6 per group). J, Percentage weight change from baseline in the groups. K, Gross morphology of colon tissue. L, Colon length in the 4 groups. M, Hematoxylin and eosin staining of colon tissue in the 4 groups. N, Histological grading of mice in each group. O, Survival in each group. P, Comparison of DAI scores among the groups. The scale bar in the panel represents 50 μm. The data are presented as the mean ± SD. *P < .05, **P < .01, ***P < .001 between groups.